KYVERNA THERAPEUTICS, INC. COMMON STOCK
NASDAQ: KYTX (Kyverna Therapeutics, Inc.)
Last update: 2 days ago, 8:59PM7.30
-0.19 (-2.54%)
| Previous Close | 7.49 |
| Open | 7.52 |
| Volume | 523,948 |
| Avg. Volume (3M) | 1,046,968 |
| Market Cap | 443,805,056 |
| Price / Book | 2.20 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2026 |
| Diluted EPS (TTM) | -3.24 |
| Total Debt/Equity (MRQ) | 3.10% |
| Current Ratio (MRQ) | 7.44 |
| Operating Cash Flow (TTM) | -133.64 M |
| Levered Free Cash Flow (TTM) | -80.19 M |
| Return on Assets (TTM) | -31.08% |
| Return on Equity (TTM) | -49.72% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Kyverna Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -3.5 |
| Technical Oscillators | -0.5 |
| Average | -2.00 |
|
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 12.04% |
| % Held by Institutions | 68.57% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Vida Ventures Advisors, Llc | 30 Sep 2025 | 4,523,924 |
| Gilead Sciences, Inc. | 31 Mar 2026 | 4,126,119 |
| Deerfield Management Company, L.P. | 31 Mar 2026 | 2,000,000 |
| Insight Holdings Group, Llc | 31 Mar 2026 | 989,054 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |